PPT-Pivotal Safety and Efficacy Results From TRANSCEND NHL 001, a Multicenter Phase 1 Study

Lisocabtagene Maraleucel in RelapsedRefractory RR Large BCell Lymphomas Abramson JS Palomba ML Gordon LI Lunning M Wang M Arnason J Mehta A Purev E Maloney DG Andreadis. Topics. Current Treatment Options for Relapsed/Refractory Multiple Myeloma. Topics. Relapsed/Refractory MM. Treatment Goals and Strategies. Relapsed/Refractory MM. Exposure to Stem Cell Toxic Agents Not An Issue for Most Patients . How and When Should it be Used in B and T cell Lymphomas. Ranjana. . Advani. MD. Professor of Medicine. Saul Rosenberg Professor of Lymphoma. Stanford University. Lymphoma and Myeloma 2014. International Congress on Hematologic Malignancies . Ruben Niesvizky. Myeloma Center. Myelomacenter.org. run9001@med.cornell.edu. Multiple Myeloma: Natural History of Disease. Durie B; International Myeloma Foundation. . Concise review of the disease and treatment options: multiple myeloma. 2011/2012 edition;. Hodgkin Lymphoma. Program Objectives. Brentuximab Vedotin in Hodgkin Lymphoma. Brentuximab Vedotin in Patients With R/R HL. Brentuximab Vedotin: Adverse Events . Nivolumab in Relapsed/Refractory HL. Pembrolizumab in Relapsed/Refractory HL. IWCLL Criteria for Treating CLL. Other Considerations at Relapse. Risk Factors at Relapse. IGHV . Status Affects Clinical Course. Case 1: 65-Year-Old Man. Assessing This Patient's Options. TP53 . Mutation/del(17p) and CIT. ASH Review 2012. Stephen Spurgeon (spurgeos@ohsu.edu). Disclosures. Speakers Bureau: GSK, . Millenium. , . Cephalon. CLL: Pertinent Topics. ASH treatment updates. James DF, et al. ASH 2011. Abstract 291.. Case Discussion A 64-year old woman diagnosed with monoclonal gammopathy of undetermined significance (MGUS ) in September 2015 She has been monitored over time and has had a slight increase in her proteins. T. ransplant . in CR on . B. rentuximab. . V. edotin. : . Allo. . Transplant . or . Maintenance . T. herapy. ?. Anas Younes, M.D.. Memorial Sloan Kettering Cancer Center. Overall Survival. <1990 median 1.9 yrs. Bertrand Coiffier. Service d. ’. Hématologie. Hospices Civils de Lyon. Equipe . « Pathologie des Cellules Lymphoïdes ». UMR 5239 CNRS – UCB – ENS - HCL. The Lymphoma. Study Association. One question, lot of possibilities. Ublituximab. , a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (. mAb. ), in Patients with Relapsing Forms of Multiple Sclerosis (RMS). Novel Glycoengineered Anti-CD20 . mAb. Unique protein sequence. Jonathon B. Cohen, MD. Dept of . Hematology. /Medical Oncology. Co-Director . Lymphoma Program. Relapsed aggressive . nhl. associated with shortened survival. Scholar-1 (Crump et al, Blood 2017). Martin et al, Blood 2016. Precursor B- and T-cell . neoplasms. Precursor B-lymphoblastic leukemia/lymphoma. Precursor T-lymphoblastic leukemia/lymphoma. Mature B-cell . neoplasms. Marginal zone B-cell lymphoma. Follicular lymphoma. Chimeric Antigen Receptor Tcell TherapyClinical Guideline Effective August 4, 2022 ��Table of Contents��THIS DOCUMENT IS PROPRIETARY AND CONFIDENTIAL TO OPTUMUnauthorized u +. Peripheral T-Cell Lymphoma: A Phase 2 Study (LuminICE-203). Alison Moskowitz. 1. , Andreas Harstrick. 2. , Michael Emig. 2. , Andre Overesch. 2. ,. . Sheena Pinto. 2. , . Paulien Ravenstijn. 2.